#Canada #High Tide #Calgary #medical cannabis #Remexian

High Tide's Remarkable Achievement in Medical Cannabis Distribution

High Tide Inc., a prominent cannabis enterprise based in Calgary, Canada, has made headlines with a groundbreaking announcement regarding its subsidiary Remexian Pharma GmbH. For the second fiscal quarter ending April 30, 2026, Remexian reported a distribution of an impressive 7.6 tonnes of medical cannabis in Germany. This figure marks not only a record for the company but also highlights a commendable 21% increase in distribution compared to the previous quarter and a staggering 49% increase year-over-year.

The Growth of Medical Cannabis in Germany

Germany is witnessing a burgeoning market for medical cannabis, having imported a total of 201.1 tonnes in 2025, which reflects more than a doubling from the 72.9 tonnes imported the previous year. High Tide's strategic positioning and its partnership with Remexian have evidently contributed to this upward trend, facilitated by the company’s ability to source from 19 countries, including Canada, which supplied a significant chunk of these imports.

High Tide’s CEO, Raj Grover, expressed his enthusiasm, stating, “This level of sequential and year-over-year growth reinforces our conviction that Germany is only the beginning. We are building a repeatable, capital-efficient distribution engine that can be expanded across Europe.” With this progress, High Tide aims to enhance its market share in Germany while planning methodical entry into other high-growth European markets.

Sustainable Growth Strategies

The reported figures are part of the company's broader strategy to harness its procurement capabilities derived from significant legal cannabis sales in Canada, exceeding $2.2 billion. This expertise allows High Tide to effectively scale operations within the European landscape, particularly in the medical cannabis sector. As the company prepares to further capitalize on its success, it seeks to use this momentum as a lever to establish a robust presence across diverse markets.

The recent records may prove pivotal for High Tide as it continues to innovate and adapt within the growing cannabis landscape, supported by its operational efficiency and a well-structured distribution system. Grover's comments on leveraging their success indicate a forward-thinking approach, prioritizing sustainable growth as they enhance their operational capabilities in anticipation of increasing demand.

Looking Ahead

While the current figures are preliminary and subject to change upon the release of the second fiscal quarter financial results in June 2026, the trajectory suggests a positive outlook for High Tide and its subsidiaries. With Germany emerging as a major player in the medical cannabis market, High Tide stands at the forefront, ready to navigate the evolving regulatory environment and capture further market opportunities.

High Tide Inc. not only leads within the Canadian context but is also setting benchmarks in international markets through strategic expansions. Remexian aims to solidify its position in the German market by ensuring an affordable, consistent supply of medical cannabis, further advocating for accessibility and reliability in this fast-evolving industry.

In conclusion, as High Tide continues to push forward, the recent distribution success underscores the company’s commitment to innovation and leadership in the cannabis space. The ongoing developments will be paramount as they shape the future of medical cannabis distribution in Europe and beyond.